These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29340601)

  • 21. Localized Pancreatic Cancer: Multidisciplinary Management.
    Coveler AL; Herman JM; Simeone DM; Chiorean EG
    Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current standards and new innovative approaches for treatment of pancreatic cancer.
    Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
    Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
    Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F
    Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.
    Ono A; Murakami Y; Abdel-Wahab M; Nagata Y
    J Gastrointest Oncol; 2022 Apr; 13(2):885-897. PubMed ID: 35557564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
    Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
    Wang G; Zhou D
    Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
    Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
    Furuse J
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
    di Sebastiano P; Grottola T; di Mola FF
    Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.